Chemical Property of Fenoprofen
Edit
Chemical Property:
- Melting Point:25°C
- Refractive Index:nD25 1.5742
- Boiling Point:381.3 °C at 760 mmHg
- PKA:4.5(at 25℃)
- Flash Point:141.7 °C
- PSA：46.53000
- Density:1.183 g/cm3
- LogP:3.66700
- Storage Temp.:Refrigerator
- Solubility.:Chloroform (Slightly), DMSO (Slightly), Methanol (Sparingly)
- Water Solubility.:0.1g/L(37 oC)
- Purity/Quality:
-
98%,99%, *data from raw suppliers
FENOPROFEN 95.00% *data from reagent suppliers
Safty Information:
- Pictogram(s):
- Hazard Codes:
- MSDS Files:
-
SDS file from LookChem
Useful:
-
Uses
antiinflammatory Fenoprofen is used in treating symptoms of rheumatoid arthritis and osteoarthritis;
however, fenoprofen exhibits a number of undesirable side effects.
-
Indications
Fenoprofen (Nalfon) is chemically and pharmacologically
similar to ibuprofen and is used in the treatment
of rheumatoid arthritis, osteoarthritis, and mild to
moderate pain. GI effects such as dyspepsia and pain
are most common, although dizziness, pruritus, and palpitations
may occur. GI bleeding, sometimes severe, has
been reported, and interstitial nephritis has been rarely
associated with this drug. Concomitant administration
of aspirin decreases the biological half-life of fenoprofen
by increasing the metabolic clearance of hydroxylated
fenoprofen. Chronic administration of phenobarbital
also decreases the drug’s half-life.
-
Therapeutic Function
Antiinflammatory
-
Clinical Use
Clinical use
NSAID and analgesic
-
Drug interactions
Potentially hazardous interactions with other drugs ACE inhibitors and angiotensin-II antagonists:
increased risk of hyperkalaemia and nephrotoxicity;
reduced hypotensive effect. Analgesics: avoid concomitant use with other
NSAIDs or aspirin; avoid concomitant use with
ketorolac (increased side effects and haemorrhage).
Antibacterials: possibly increased risk of convulsions
with quinolones.
Anticoagulants: effects of coumarins and
phenindione enhanced; possibly increased risk of
bleeding with heparin, dabigatran and edoxaban -
avoid long term use with edoxaban.
Antidepressants: increased risk of bleeding with
SSRIs or venlafaxine.
Antidiabetics: effects of sulphonylureas enhanced.
Antiepileptics: possibly enhanced effect of phenytoin.
Antivirals: concentration possibly increased by
ritonavir; increased risk of haematological toxicity
with zidovudine.
Ciclosporin: may potentiate nephrotoxicity.
Cytotoxics: reduced excretion of methotrexate;
increased risk of bleeding with erlotinib.
Diuretics: increased risk of nephrotoxicity;
antagonism of diuretic effect; hyperkalaemia with
potassium-sparing diuretics.
Lithium: excretion reduced.
Pentoxifylline: increased risk of bleeding.
Tacrolimus: increased risk of nephrotoxicity
